ArticleJAMA internal medicine2022
Guideline-Discordant Care Among Direct-to-Consumer Testosterone Therapy Platforms.
Article in JAMA internal medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Adiposity, not chronological aging, is the dominant determinant of circulating testosterone in US adult men.Journal of the Endocrine Society · 2026Article
- Discordance Between Online Information and Male Hypogonadism Clinical Guidelines: A Global Multilingual Content Analysis.The Journal of clinical endocrinology and metabolism · 2026Article
- Article
- Testosterone replacement therapy and spermatogenesis in reproductive age men.Nature reviews. Urology · 2025Review
- Streamlined Testosterone Order Template to Improve the Diagnosis and Evaluation of Hypogonadism in Veterans.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2025Article
- A Review on Testosterone: Estradiol Ratio-Does It Matter, How Do You Measure It, and Can You Optimize It?The world journal of men's health · 2025Review
- Beyond the prescription: trends and challenges in erectile dysfunction medications among young adult men.International journal of impotence research · 2025Article
- Is combined androgen and gonadotropin therapy a viable harm reduction strategy for men using high-dose exogenous androgens who are interested in family building?F&S reports · 2025Article
- The cost and guideline adherence of direct-to-consumer telemedicine companies offering gender-affirming hormone therapy.The Canadian journal of urology · 2025Article
- Article
- Evaluation and characterization of testosterone-related mobile health applications.International journal of impotence research · 2024Article
- Trends in testosterone prescription during the release of society guidelines.International journal of impotence research · 2024Article
- Cross-sectional analysis of national testosterone prescribing through prescription drug monitoring programs, 2018-2022.PloS one · 2024Article
- Article
- False or Misleading Claims in Online Direct-to-Consumer Ketamine Advertising in Maryland.JAMA network open · 2023Article
- Testosterone Prescribing in Texas, 2018-2021.Journal of general internal medicine · 2023Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.